Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
AUSTIN, Texas—Natera, Inc. (NASDAQ:NTRA), a diagnostics company with a market capitalization of $18.83 billion, recently saw stock transactions involving its President of Clinical Diagnostics, Solomon Moshkevich. On April 1, 2025, Moshkevich executed a series of stock sales totaling $421,428. The shares were sold at prices ranging from $139.7757 to $141.8997 each, near the stock’s 52-week high of $183. InvestingPro analysis indicates the stock is currently trading above its Fair Value.
According to the SEC filing, the transactions were conducted under a Rule 10b5-1 trading plan, which had been adopted by Moshkevich in November 2024. Post-transaction, Moshkevich holds 141,782 shares of Natera. The stock has shown remarkable performance with a 50% return over the past year, though InvestingPro data reveals significant price volatility. Discover more insights about Natera in the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Natera Inc . reported its fourth-quarter 2024 earnings, exceeding Wall Street expectations with a revenue of $476 million, significantly higher than the anticipated $409.89 million. This represents a 53% year-over-year increase, driven by strong demand for its Signatera product and advancements in molecular diagnostics. Analysts from TD Cowen and Canaccord Genuity have both maintained a Buy rating on Natera, with Canaccord Genuity raising its price target from $180 to $195 following the company’s impressive fourth-quarter results. Natera’s strategic spending on operational expenses has been noted as a means to fuel growth, with analysts highlighting the company’s robust growth levers, including the anticipated rise in Signatera’s price and volume.
Additionally, Natera has launched the HEROES clinical trial to explore the de-escalation of therapy in metastatic HER2+ breast cancer patients. The trial, sponsored by Unicancer and funded by the French Ministry of Health, aims to assess the feasibility of ctDNA-guided treatment de-escalation. The company is optimistic about the trial’s potential to help oncologists identify patients who could safely discontinue therapy. Furthermore, Natera achieved positive operating cash flows for the fourth consecutive quarter, indicating consistent financial performance.
Looking ahead, Natera has set its 2025 revenue guidance between $1.87 billion and $1.95 billion, suggesting a 24% growth at the midpoint. Canaccord Genuity’s analysts are optimistic about Natera’s future, especially in light of the company’s initial guidance for 2025, which suggests continued strong gross margins and positive cash flow. The firm’s confidence in Natera is further bolstered by potential benefits from likely improved Medicare Advantage rates and biomarker legislation expected in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.